News

Oncovita announces a strategic partnership with Infinitusbio.AI to explore the design and optimize the development of new therapeutic candidates from its Measovir® platform

Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma

ONCOVITA and UNITHER Pharmaceuticals partner to develop a new prophylactic vaccine based on Measovir® and Euroject® technologies

Oncovita wins Paris Saclay Cancer Cluster award

Oncovita appoints Stéphane Altaba as Chief Executive Officer

Oncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immunotherapy and prophylactic vaccinology

Oncovita raise 8M€ to support the development of its MVdeltaC immunotherapeutic vaccine in oncology

MVdeltaC: a new therapeutic vaccine derived from measles vaccine with promising preclinical immuno-oncolytic activities (Abstract)

Three-in-one Vaccine: A Single Recombinant Measles Virus Expressing Three Arbovirus Antigens Induces Robust Humoral and Cell-Mediated Immune Responses, Conferring Effective Protection in a Mouse Model (Abstract)

Oncovita presents preclinical data on its promising MVdeltaC oncolytic vaccine at SITC Annual Meeting 2022, Nov 8. (Engl / Fr)